Tag:
Gilenya
Latest Headlines
Latest Headlines
European regulators tag 100-plus drugs with 'black triangle'
The labeling logo is designed to encourage doctors and patients to report side effects, as part of a new effort to more closely monitor drug safety. The list of 100-plus products includes all new drugs and biologics approved since January 2011.
Novartis aims new Gilenya campaign at young MS patients
Novartis is thinking young. The Swiss drugmaker is using a cheeky ad campaign, targeted at 20- and 30-somethings not only in magazines, but via websites and social media. Novartis needs to find a new edge in the MS market, where it faces not only well-established injectable drugs, but two new oral rivals.
Biogen prices Tecfidera below oral MS rival Gilenya
Biogen Idec's ($BIIB) newly approved Tecfidera has a wholesale price of $54,900 per year, the biotech giant revealed on Friday. With the U.S. market debut of the oral multiple sclerosis drug set for Monday, Biogen plans to hit the market for MS pills with a lower price than Novartis' ($NVS) Gilenya, which is arguably the company's top competition.
Novartis MS drug could help beat bowel cancer
Novartis' multiple sclerosis drug Gilenya (fingolimod) could treat or even prevent colitis-associated cancer, if preclinical findings from U.S. researchers can be confirmed in later studies.
Eyeing Biogen drug, Teva demands review for new MS meds
Teva Pharmaceutical Industries ($TEVA) is very proud of its multiple sclerosis drug Copaxone. Thing is, Copaxone goes off patent in 2015.
Overnight success proves elusive for oral MS drugs
Theoretically, the advent of oral MS treatments was supposed to drain sales away from less-convenient injectables--and quickly. In practice, patients and doctors have proven more cautious about the newer drugs, The Wall Street Journal reports.
Novartis, Sanofi unveil data backing their rival MS pills
Novartis is touting a new data analysis suggesting that early treatment with its multiple sclerosis drug Gilenya can ward off relapses--and even prevent the loss of brain volume that often plagues MS patients. It's just one of the studies Novartis hopes will support increased use of its MS pill, the first oral therapy for the disease when it was launched last year.
Biogen, Sanofi and Novartis stoke oral MS drug rivalry with clinical data
Three contenders in the oral multiple sclerosis drug race have spotlighted their rival therapies this week. Biogen Idec, which revealed analysis from two Phase III studies of its blockbuster hopeful BG-12, is providing the new data points as the biotech heavyweight seeks approval of the oral med in the U.S. and Europe.
Aubagio approval sets Sanofi up with possible blockbuster
In these days of patent losses, falling revenues and massive layoffs, Sanofi could use some good news, and it got some late Wednesday with the FDA approval of its new multiple sclerosis (MS) drug Aubagio, a possible blockbuster if it can sweep up market share from some tough competitors.
JAMA says FDA jumped the gun on Gilenya, Pradaxa
The FDA's balancing act is no easy feat. In fact, it just might be impossible. As soon as the agency gets Congressional direction to revamp and speed up approvals, experts in other quarters conclude that approvals are coming too fast.
